Medy-Tox Inc Total Assets
Medy-Tox Inc total assets. Based on the latest financial reports, Medy-Tox Inc (086900) holds total assets worth ₩586.91 Billion KRW (≈ $397.74 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Medy-Tox Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Medy-Tox Inc (2013–2024)
Total assets of Medy-Tox Inc from 2013 to 2024. This chart illustrates how Medy-Tox Inc's total assets have evolved over time, based on quarterly financial data. See 086900 share price today for real-time trading data and today's change.
Medy-Tox Inc - Asset Composition Analysis
Medy-Tox Inc Total Assets Breakdown (December 2024)
Medy-Tox Inc total assets breakdown as of December 2024. Medy-Tox Inc's total assets of ₩586.91 Billion consist of 30.3% current assets and 69.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩45.65 Billion | 7.5% |
| Accounts Receivable | ₩53.88 Billion | 8.8% |
| Inventory | ₩64.26 Billion | 10.5% |
| Property, Plant & Equipment | ₩200.27 Billion | 32.6% |
| Intangible Assets | ₩63.89 Billion | 10.4% |
| Goodwill | ₩8.14 Billion | 1.3% |
Asset Composition Trend (2013–2024)
This chart illustrates how Medy-Tox Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Medy-Tox Inc (086900) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medy-Tox Inc's current assets represent 30.3% of total assets in 2024, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, up from 5.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is property, plant & equipment at 32.6% of total assets.
Medy-Tox Inc Competitors by Total Assets
Key competitors of Medy-Tox Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Disc Medicine Inc.
NASDAQ:IRON
|
USA | $735.07 Million |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
USA | $104.69 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
Medy-Tox Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.35 | 1.18 |
| Quick Ratio | 1.30 | 0.81 | 0.86 |
| Cash Ratio | 0.00 | 0.23 | 0.00 |
| Working Capital | ₩75.11 Billion | ₩42.24 Billion | ₩21.12 Billion |
Medy-Tox Inc - Advanced Valuation Insights
This section examines the relationship between Medy-Tox Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.6% |
| Total Assets | ₩615.16 Billion |
| Market Capitalization | $315.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medy-Tox Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Medy-Tox Inc's assets grew by 0.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medy-Tox Inc (2013–2024)
The table below shows the annual total assets of Medy-Tox Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩615.16 Billion ≈ $416.89 Million |
+0.58% |
| 2023-12-31 | ₩611.62 Billion ≈ $414.49 Million |
+2.57% |
| 2022-12-31 | ₩596.29 Billion ≈ $404.10 Million |
+3.22% |
| 2021-12-31 | ₩577.70 Billion ≈ $391.50 Million |
+23.50% |
| 2020-12-31 | ₩467.76 Billion ≈ $317.00 Million |
+10.97% |
| 2019-12-31 | ₩421.53 Billion ≈ $285.66 Million |
+6.71% |
| 2018-12-31 | ₩395.01 Billion ≈ $267.70 Million |
+3.69% |
| 2017-12-31 | ₩380.95 Billion ≈ $258.16 Million |
+17.56% |
| 2016-12-31 | ₩324.03 Billion ≈ $219.59 Million |
+59.19% |
| 2015-12-31 | ₩203.55 Billion ≈ $137.94 Million |
+20.79% |
| 2014-12-31 | ₩168.51 Billion ≈ $114.20 Million |
+112.19% |
| 2013-12-31 | ₩79.41 Billion ≈ $53.82 Million |
-- |
About Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more